Genfit - ADR

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Earnings data Q1 2024

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the April 15, 2024 French legal announcements bulletin n°46 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 10:00am (CET), at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the filing of its 2023 Universal Registration Document with the Autorité des marchés financiers (AMF ; filing n° D.24-0246) and its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission (SEC).

GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

Lille, France; Cambridge, MA; Zurich, Switzerland; April 4, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced annual financial results for the year ended December 31, 2023. A summary of the consolidated financial statements is included below.

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of December 31, 2023 and revenues for 2023.

GENFIT Announces Revenues and Cash Position as of December 31, 2023

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024.

GENFIT Announces 2024 Financial Calendar

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 8, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its revised outlook for 2024 and reflects on recent progress.

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 6, 2023- GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the publication in the Journal of Hepatology 2 of a paper on the performance of NIS2+™ as a screening tool for the enrollment of patients in Metabolic Dysfunction–Associated Steatohepatitis (MASH) clinical trials.

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

Genfit is close to possible approval for its drug team-up with Ipsen, with positive Phase 3 readouts having been achieved. The company focuses on developing therapeutic products for liver diseases, currently with a primary focus on Primary Biliary Cholangitis (PBC). Genfit's cash situation is decent, with most of its debt being convertible and maturing in a distant enough future, giving the company time for key approvals.

Genfit: Large PBC Market, Liquidity To Await Approval

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 16, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the highlights from its “ACLF Day” held on November 11, 2023 during AASLD The Liver Meeting ® in Boston, MA (USA).

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Paris (France), November 13, 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session (Abstract #484, Monday, 13 November at 16.45 EST) at the American Association for the Study of Liver Diseases (AASLD) and simultaneously published in New England Journal of Medicine (NEJM). This trial evaluated the efficacy and safety of investigational elafibranor, an oral, dual PPAR α,δ agonist, as a potential novel class of treatment for patients with the rare, autoimmune cholestatic liver disease, Primary Biliary Cholangitis (PBC).

GENFIT: Results from Ipsen's ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); November 9, 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of September 30, 2023 and revenue for the first nine months of 20231.

GENFIT Reports Third Quarter 2023 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present an update on its scientific and corporate progress at The Liver Meeting® 2023 organized by the American Association for the Study of Liver Diseases (AASLD), which will take place in Boston, MA (USA) from November 10-14, 2023.

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); September 2 6 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of data demonstrating the effectiveness of its non-alcoholic steatohepatitis (NASH)1 diagnostic technology NIS4® by the FNIH's2 NIMBLE 3 project in the scientific journal, Nature Medicine 4 .

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology

After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support.

GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) , September 05 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will participate in the following upcoming investor conferences.

GENFIT to Participate in Upcoming Investor Conferences

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); August 10 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of new data on the clinical performance of NIS2+™ in older patients, for the detection of at-risk nonalcoholic steatohepatitis (NASH) in Hepatology Communications 1.

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

GENFIT (NASDAQ:GNFT) shares fell 5% after initially rising on positive results from its clinical trial with partner Ipsen for the investigational therapeutic elafibranor in patients with the rare cholestatic liver disease primary biliary cholangitis (PBC).   The two companies announced on Friday that the Phase 3 ELATIVE trial met its primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to the placebo.

Genfit shares fall despite positive trial results for rare cholestatic liver disease therapeutic

Apple

NIKE

Here comes the third quarter, next stop, the rest of the year. Judging by stock futures action, the first half could end on a positive note.

These strategists say investors need quality, so sell Tesla and AMD, and buy these stocks instead.

The U.S.-listed stock of Genfit S.A. GNFT, -5.48% GNFT, +22.56% soared 27% premarket Friday, after the French biotech and partner Ipsen IPSEY, +7.22% IPN, +0.27% announced positive results from a late-stage trial of a treatment for a rare liver disease.

U.S.-listed shares of Genfit soar 24% after positive results from late-stage trial of treatment for rare type of liver disease

Paris ( France ) ; Ju ne 30 , 202 3 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE® Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is being assessed for the treatment of patients with the rare cholestatic liver disease, primary biliary cholangitis (PBC), who have an inadequate response or intolerance to the current standard of care therapy, ursodeoxycholic acid (UDCA).

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

PARIS, FRANCE, 30 June   20 23 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α,δ PPAR agonist, is being assessed for the treatment of patients with the rare cholestatic liver disease, primary biliary cholangitis (PBC), who have an inadequate response or intolerance to the current standard of care therapy, ursodeoxycholic acid (UDCA).

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland ); June 7 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced that it will present new data at the EASL Congress which will take place on June 21-24, 2023 in Vienna, Austria.

GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE , May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutics is eligible for payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties.

Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); Ma y 3 1 , 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs, today announced it has licensed the exclusive worldwide rights of ASK1 Inhibitor SRT-015 (injectable formulation in acute liver disease2) from Seal Rock Therapeutics, a Seattle, Washington (USA) based clinical stage company developing first-in-class and best-in-class kinase inhibitors.

News for Genfit - ADR Stock (GNFT)